Biological markers for longevity and diseases and uses thereof

• US 8,399,258 B2
• Filed: 12/05/2008
• Issued: 03/19/2013
• Est. Priority Date: 03/20/2003
• Status: Active Grant

• Current Assignee: Albert Einstein College of Medicine (Yeshiva University)
• Original Assignee: Albert Einstein College of Medicine of Yeshiva University
• Inventors: Barzilai, Nir
• Primary Examiner(s): KAM, CHIH MIN
• Application Number:
  US12/315,845
• Publication Number:
  US 20090155915A1
• Time in Patent Office: 1,565 Days
• Field of Search: 530/359, 436/71
• US Class Current: 436/71
• CPC Class Codes: C12Q 1/48 involving transferase
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: G01N 2800/04 Endocrine or metabolic disorders
• CPC Class Codes: G01N 2800/042 Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
• CPC Class Codes: G01N 2800/2814 Dementia; Cognitive disorders
• CPC Class Codes: G01N 2800/2871 Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
• CPC Class Codes: G01N 2800/32 Cardiovascular disorders
• CPC Class Codes: G01N 2800/321 Arterial hypertension
• CPC Class Codes: G01N 2800/324 Coronary artery diseases, e.g. angina pectoris, myocardial infarction
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere
• CPC Class Codes: G01N 33/92 involving lipids, e.g. cholesterol , lipoproteins, or their receptors steroid hormones G01N33/743

Abstract

This invention provides methods of using of the sizes and levels of high-density lipoprotein (HDL) and low-density lipoprotein (LDL) particles, the −641 allele of the promoter of the gene encoding apolipoprotein C-3 (APOC-3), the 405 allele of the gene encoding cholesteryl ester transfer protein (CETP), and plasma levels of insulin-like growth factor-1 (IGF-1), adiponectin, CETP and APOC-3, for determining and increasing an individual'"'"'s likelihood of longevity and of retaining cognitive function during aging, and for determining and decreasing an individual'"'"'s likelihood of developing a cardiovascular-, metabolic- or age-related disease.

Claims

1. A method for identifying a compound for decreasing hypertension and/or increasing insulin sensitivity in a subject, the method comprising

determining whether or not a compound inhibits the activity of apoliprotein C-3 (APOC-3) from a subject, wherein a compound that inhibits the activity of apoliprotein C-3 (APOC-3) is identified as a putative compound for decreasing hypertension and/or increasing insulin sensitivity, and

determining whether or not the compound decreases hypertension and/or increases insulin sensitivity in the subject.

2. The method of claim 1, wherein the compound inhibits the activity of apolipoprotein C-3 (APOC-3).

3. The method of claim 1, wherein the compound is a putative compound for decreasing hypertension.

4. The method of claim 1, wherein the compound is a putative compound for increasing insulin sensitivity.

5. A method for identifying a compound for decreasing hypertension and/or increasing insulin sensitivity in a subject, the method comprising

identifying a compound that inhibits the activity of apoliprotein C-3 (APOC-3) from the subject, and

determining whether or not the compound that inhibits apoliprotein C-3 (APOC-3) activity decreases hypertension and/or increases insulin sensitivity in the subject.

6. The method of claim 5, wherein the compound decreases hypertension.

7. The method of claim 5, wherein the compound increases insulin sensitivity.